Table 1.
Clinical characteristics and treatments of study participants by group
| SBRT + IL-2 | IL-2 | |
| Male | 18 | 16 |
| Female | 6 | 4 |
| Age (mean) | 53 | 57.5 |
| BRAF status | ||
| Mutated/wild type/unknown | 7/14/3 | 11/5/4 |
| Baseline LDH (mean) (upper limit of normal 268 IU/L) | 389 | 263 |
| Prior therapy | ||
| Surgery (%) | 24 (100) | 20 (100) |
| Radiation (n) | 1 (4) | 3 (15) |
| BRAF therapy (n) | 1 | 0 |
| Immune checkpoint (n) | 5 | 3 |
| Subsequent therapy | ||
| BRAF therapy (n) | 4 | 5 |
| Immune checkpoint (n) | 11 | 6 |
| Metastatic sites at start of treatment | ||
| Lung (%) | 64 | 74 |
| Liver (%) | 36 | 37 |
| Lymph node (%) | 36 | 53 |
| Bone (%) | 14 | 5 |
| Subcutaneous (%) | 27 | 11 |
| Brain (%) | 5 | 5 |
| Soft tissue (%) | 50 | 21 |
| Adrenal (%) | 14 | 0 |
| Sum of diameters of target lesions using modified RECIST | ||
| cm (median) | 8.2 | 6.5 |
| cm (mean) | 5.1 | 5.3 |
| Sum of diameters of 30 largest lesions | ||
| cm (median) | 19.7 | 13.7 |
| cm (mean) | 11.4 | 10.7 |
LDH, lactate dehydrogenase; RECIST, Response Evaluation Criteria in Solid Tumors.